Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $381.44.

Several brokerages have recently commented on MEDP. TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. R Squared Ltd purchased a new stake in Medpace in the fourth quarter valued at $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace in the fourth quarter worth about $31,000. Stone House Investment Management LLC acquired a new stake in Medpace during the third quarter worth about $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the third quarter valued at approximately $37,000. Finally, Jones Financial Companies Lllp raised its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of Medpace stock opened at $336.47 on Thursday. The company has a market capitalization of $10.46 billion, a PE ratio of 29.46, a P/E/G ratio of 1.85 and a beta of 1.36. The company has a 50-day simple moving average of $343.90 and a two-hundred day simple moving average of $348.96. Medpace has a one year low of $302.01 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. On average, equities analysts predict that Medpace will post 11.93 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.